koto_feja/E+ via Getty Images

Alaunos Therapeutics (NASDAQ:TCRT) fell ~17% on Friday as investors reacted to data from a Phase 1/2 trial for its T-cell receptor (TCR) cell therapy candidate in patients with solid tumors harboring KRAS or TP53 genetic mutations.

As of Feb. 2023, out of three patients

Source link

You May Also Like

Want to Live a Longer, More Satisfying Life? Reverse-Engineer Your Ideal Later Years With the Centenarian Decathlon

Just pick 10 things you want to do when you’re 80 or…

IMAX teams with Cineplexx Austria on three new locations (NYSE:IMAX)

IMAX teams with Cineplexx Austria on three new locations Source link

British coins tested for quality in 700-year-old ‘Trial of the Pyx’

Britain’s coins have been tested for their metallic composition, weight and size…

What Home Depot’s billion-dollar pay raise may help prove about workers

Workers walk through the garden center at a Home Depot store Scott…